Navigation Links
TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Date:8/19/2007

- Top Line Results Expected to Be Reported in 4Q 2007 -

LA JOLLA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has completed enrollment in its Phase IIb clinical trial of tezampanel for the treatment of acute migraine headache. Tezampanel is an AMPA/kainate (AK) receptor antagonist that offers a non-opioid, non-vascular and non-serotonergic approach to the management of pain and represents a potentially new and promising alternative to current migraine treatments.

The clinical trial is a double-blind, placebo-controlled, multi-center trial that reached its targeted enrollment of 300 patients suffering a single migraine attack, with or without aura. Patients are randomized to one of four arms and receive a 40 mg, 70 mg, or 100 mg single, subcutaneous dose of tezampanel or placebo. The purpose of the trial is to identify a dose, or a range of doses, that could be used in a Phase III development program for tezampanel in acute migraine. The primary efficacy endpoint for the trial is headache pain relief at two hours post-dose. Secondary efficacy endpoints include pain free status at two hours, sustained pain relief and sustained pain free at 24 hours, and headache recurrence and relapse. Additional measures include assessments of functional disability and patient satisfaction, relief of migraine-associated symptoms such as nausea, vomiting, photophobia (sensitivity to light) and phonophobia (sensitivity to sound), as well as various assessments that characterize speed of treatment onset. Safety, tolerability and plasma pharmacokinetic data will also be evaluated.

"Completing enrollment in our Phase IIb trial with tezampanel is an i
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014  Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, said ... conferences. On Tuesday, December 2, the company ... Jaffray Healthcare Conference.  D. Keith Grossman , President ... the company beginning at 11:30 a.m., Eastern Standard Time ...
(Date:11/26/2014)... Company plc ("Perrigo") (NYSE: PRGO ; TASE), ... today announced the closing of Perrigo,s previously announced registered ... shares at a public offering price of $152.00 per ... purchase up to an additional 888,157 ordinary shares by ... representatives of the several underwriters. Perrigo ...
(Date:11/26/2014)... , Nov. 26, 2014 Lexicon Pharmaceuticals, ... the completion of previously announced concurrent financing transactions ... fees and estimated offering expenses, Lexicon anticipates net ...  The transactions consisted of: , a ... pursuant to a registration statement that has been ...
Breaking Medicine Technology:Thoratec Announces Presentations At Investor Conferences For December 2014 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3
(Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “LAB.C” ... Report, which features the latest and coolest technology products available ... NewsWatch, conducted the product review and shared with ... cable for iOS and Android devices. , Consumers love portability ... LAB.C. Their Cable Case for the iPhone5 and 5S ...
(Date:11/27/2014)... Dallas, Texas (PRWEB) November 27, 2014 ... research report on Global Insulin industry. For an ... including definition, classification, application, industry chain structure, industry ... report on global Insulin industry covers information ... manufacturing process, product cost structure and much more. ...
(Date:11/27/2014)... Allowing children to help with chores while ... give children responsibility, ownership, boosts self-esteem, and above all, helps ... the real question is, how do you encourage your children ... a study published by Child Development Journal, there is. The ... on a child’s willingness to lend a hand. , ...
(Date:11/27/2014)... November 27, 2014 RBSEO Services, ... search engine optimization service just at $99. RBSEO ... start-ups cannot afford costly search engine optimization service. ... keeping their affordablity and requirements into consideration. ... but it has not compromised with the service ...
(Date:11/27/2014)... 2014 Ethane Web Technologies, an ISO 9001: ... a 10% Christmas discount on PPC service. The discount will ... offer will begin on 1 December 2014 and remain valid ... offer, a PPC professional working at Ethane Web Technologies says, ... businesses, as this big discount would make the service quite ...
Breaking Medicine News(10 mins):Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3Health News:RBSEO Services Announces SEO Services at $99 Only 2Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
... team of doctors in Himachal Pradesh have removed an 18 ... was performed Wednesday at a hospital in Kullu, 240 km ... in Mandi district had reported at the hospital with pain ... 90 minutes to remove the hard oval shaped tumour from ...
... findings of a study shed light on a nagging mystery ... contain// considerable pools of free zinc ions. Zinc - a ... regulate neuronal signaling in the brain and spinal cord – ... a mutation affecting a neuronal zinc target, researchers have demonstrated ...
... to the general public as the number of reported infections ... Daily said// Wednesday. ,The latest statistics from the ... to 183,733 this year, up from 144,089 at the end ... 40,667 have developed into AIDS. ,"Health officials attributed ...
... called bivalirudin (Angiomax) that beats the standard combination drug ... heart// attacks. This new blood thinner seems to be ... ,The Results of the ‘Acute Catheterization and ... November issue of the New England Journal of Medicine. ...
... a widely used medication to strengthen fragile, aging bones ... recent study led by Johns Hopkins// rheumatologist Clifton Bingham, ... might be used to treat osteoarthritis after noticing that ... of drugs, not only slowed joint damage in animals, ...
... and adolescents are enjoying the health and social ... observers have noted problems related to// over-competitiveness and ... alarming increases in sport-related injuries in young athletes. ... Sport Medicine is a special Thematic Issue providing ...
Cached Medicine News:Health News:Zinc – A New Key Player In Brain Circuitr 2Health News:Alarming Rise in HIV Cases in China: Report 2Health News:New Anti-Clotting Drug Less Risky For Heart Attack Patients 2Health News:Millions with Arthritis May Benefit from Bone Loss Drug 2Health News:Kids in Sport—Great for Fitness, but Concern About Injurie 2Health News:Kids in Sport—Great for Fitness, but Concern About Injurie 3
Cross action, round handle, maximum opening 2.8 mm....
Irrigating nucleus chopper, 1.5 mm long wedge-shaped, inferior edge with round end, 0.6 mm dual sideports 20 gauge....
Phaco chopper elongated Kuglen style push-pull tip with wedge shaped superior and inferior edges. For bi-directional chopping....
... Floor Plates feature a unique design for ... a CP titanium and .3mm thick for ... for optimal malleability. Universal (left/right) anatomical shape ... out and smooth construction for optimal safety. ...
Medicine Products: